MCID: CRV031
MIFTS: 52

Cervical Adenocarcinoma

Categories: Reproductive diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Cervical Adenocarcinoma

MalaCards integrated aliases for Cervical Adenocarcinoma:

Name: Cervical Adenocarcinoma 12 56 52 14 69
Adenocarcinoma of the Uterine Cervix 12
Adenocarcinoma of Cervix Uteri 56
Adenocarcinoma Cervix Uteri 12
Adenocarcinoma of Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3702
NCIt 47 C4029
Orphanet 56 ORPHA213772
UMLS via Orphanet 70 C0279672
ICD10 via Orphanet 34 C53.0 C53.1 C53.8
UMLS 69 C0279672

Summaries for Cervical Adenocarcinoma

Disease Ontology : 12 A cervix carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Cervical Adenocarcinoma, also known as adenocarcinoma of the uterine cervix, is related to adenocarcinoma in situ and endocervicitis. An important gene associated with Cervical Adenocarcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Immune response IL-23 signaling pathway. The drugs Gardasil and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include cervix, lung and lymph node, and related phenotypes are cellular and digestive/alimentary

Related Diseases for Cervical Adenocarcinoma

Diseases in the Cervical Adenocarcinoma family:

Early Invasive Cervical Adenocarcinoma

Diseases related to Cervical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 274)
id Related Disease Score Top Affiliating Genes
1 adenocarcinoma in situ 30.8 CDKN2A CDX2 KRT7 TP53
2 endocervicitis 30.1 ERBB2 TP53
3 nasopharyngeal carcinoma 29.3 CDKN1A CDKN2A EGFR TP53
4 lung cancer 26.2 CDKN1A CDKN2A EGFR ERBB2 KRT20 KRT7
5 early invasive cervical adenocarcinoma 12.0
6 glassy cell carcinoma of the cervix 11.1
7 cervical adenoid cystic carcinoma 10.8 CDKN2A TP53
8 brachial amelia, forebrain defects and facial clefts 10.8 CDKN2A PTGS2
9 tendon sheath lipoma 10.8 PTGS2 TP53
10 rhinosporidiosis 10.8 CDX2 KRT20
11 split hand split foot nystagmus 10.8 CDKN2A TP53
12 leiomyoma cutis 10.8 CDKN2A TP53
13 cushing's syndrome 10.8 CDX2 PTGS2
14 cervical adenitis 10.8 CDKN2A KRT7
15 anal squamous cell carcinoma 10.7 CDKN2A TP53
16 gastric adenocarcinoma 10.7 CDX2 KRT20
17 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 10.7 CDKN2A EGFR
18 cervicitis 10.7
19 adenocarcinoma 10.7
20 bone giant cell tumor 10.7 KRT20 KRT7
21 breast mucinous cystadenocarcinoma 10.7 CDX2 KRT20
22 small intestine leiomyoma 10.7 KRT20 TP53
23 rectum adenoma 10.7 KRT20 KRT7
24 pediatric infratentorial ependymoma 10.7 EGFR TP53
25 intrahepatic bile duct adenoma 10.7 KRT20 TP53
26 extrahepatic bile duct adenoma 10.7 KRT20 TP53
27 periosteal osteogenic sarcoma 10.7 KRT20 KRT7
28 rectum squamous cell carcinoma 10.7 CDKN2A TP53
29 steroid-induced glaucoma - borderline 10.7 KRT20 KRT7
30 childhood teratoma of the ovary 10.7 CDX2 KRT20
31 ludwig's angina 10.7 KRT20 KRT7
32 malignant giant cell tumor of soft parts 10.7 CDKN2A EGFR
33 clear cell squamous cell skin carcinoma 10.7 KRT20 KRT7
34 small intestine cancer, childhood 10.7 KRT20 KRT7
35 bile duct mucinous adenocarcinoma 10.7 CDX2 KRT7
36 lipid-cell variant infiltrating bladder urothelial carcinoma 10.7 KRT7 TP53
37 central nervous system organ benign neoplasm 10.6 ESR1 TP53
38 stromal predominant kidney wilms' tumor 10.6 CDX2 KRT7
39 fallopian tube clear cell adenocarcinoma 10.6 ESR1 TP53
40 lung adenoma 10.6 ESR1 TP53
41 neuroendocrine tumor 10.6 CDX2 KRT20 PTGS2
42 giant cell tumor 10.6 CDX2 KRT20
43 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 10.6 EGFR TP53
44 testicular trophoblastic tumor 10.6 KRT20 KRT7
45 sarcomatoid squamous cell skin carcinoma 10.6 CDKN2A ESR1
46 esophagus squamous cell carcinoma 10.6 CDKN2A PTGS2 TP53
47 coccidiosis 10.6 CDKN2A TP53
48 advanced sleep phase syndrome 10.6 CDKN2A CDX2 TP53
49 rete testis neoplasm 10.6 CDKN2A EGFR PTGS2
50 intestinal perforation 10.6 ESR1 TP53

Graphical network of the top 20 diseases related to Cervical Adenocarcinoma:



Diseases related to Cervical Adenocarcinoma

Symptoms & Phenotypes for Cervical Adenocarcinoma

MGI Mouse Phenotypes related to Cervical Adenocarcinoma:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 CDKN1A CDKN2A CDX2 EGFR ERBB2 ESR1
2 digestive/alimentary MP:0005381 10.26 CDKN1A CDKN2A CDX2 EGFR ERBB2 ESR1
3 homeostasis/metabolism MP:0005376 10.26 KRT7 PTGS2 RASSF1 TP53 VIL1 CDKN1A
4 cardiovascular system MP:0005385 10.23 CDKN1A CDKN2A CDX2 EGFR ERBB2 ESR1
5 endocrine/exocrine gland MP:0005379 10.19 CDKN1A CDKN2A CDX2 EGFR ERBB2 ESR1
6 mortality/aging MP:0010768 10.16 CDKN1A CDKN2A CDX2 EGFR ERBB2 ESR1
7 embryo MP:0005380 10.15 EGFR ERBB2 ESR1 PTGS2 TP53 CDKN1A
8 integument MP:0010771 10.11 CDKN1A CDKN2A EGFR ERBB2 ESR1 LAMC2
9 neoplasm MP:0002006 10.06 CDKN1A CDKN2A CDX2 EGFR ERBB2 ESR1
10 limbs/digits/tail MP:0005371 10.04 CDKN1A CDX2 EGFR ERBB2 ESR1 LAMC2
11 liver/biliary system MP:0005370 10.02 CDKN1A CDKN2A EGFR ESR1 PTGS2 RASSF1
12 muscle MP:0005369 9.98 EGFR ERBB2 ESR1 PTGS2 TP53 CDKN1A
13 normal MP:0002873 9.92 CDX2 EGFR ERBB2 ESR1 PTGS2 RASSF1
14 no phenotypic analysis MP:0003012 9.85 TP53 CDKN1A CDKN2A EGFR ESR1 PTGS2
15 renal/urinary system MP:0005367 9.8 TP53 CDKN1A EGFR ESR1 KRT7 LAMC2
16 reproductive system MP:0005389 9.76 CDKN1A CDKN2A CDX2 EGFR ERBB2 ESR1
17 respiratory system MP:0005388 9.56 CDKN1A CDKN2A EGFR ERBB2 ESR1 LAMC2
18 skeleton MP:0005390 9.28 CDKN1A CDKN2A CDX2 EGFR ERBB2 ESR1

Drugs & Therapeutics for Cervical Adenocarcinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Gardasil 17 46 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006

Drugs for Cervical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 201)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
2 Epoetin alfa Phase 4,Phase 3 113427-24-0
3 Hematinics Phase 4,Phase 3,Phase 2
4 Vaccines Phase 4,Phase 3,Phase 2
5
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
6
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
7
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
8
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
9
Levoleucovorin Approved Phase 3,Phase 1,Phase 2 68538-85-2
10
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
11
Capecitabine Approved, Investigational Phase 2, Phase 3, Phase 1 154361-50-9 60953
12
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
13
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
14
Vinblastine Approved Phase 3,Phase 2 865-21-4 13342 241903
15
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
16
Bleomycin Approved Phase 3 11056-06-7 5360373
17
Ifosfamide Approved Phase 3 3778-73-2 3690
18
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
19
Vindesine Approved Phase 3 59917-39-4, 53643-48-4 40839
20
Doxepin Approved Phase 3 1668-19-5 667477 667468
21
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
22
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
23
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
24
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
25
Epirubicin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 56420-45-2 41867
26
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
27
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
28
Ondansetron Approved Phase 3 99614-02-5 4595
29
Ranitidine Approved Phase 3 66357-59-3, 66357-35-5 3001055
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
31
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 143 6006
32
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
33
Vatalanib Investigational Phase 3 212141-54-3 151194
34
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
35 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
36 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
37 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
38 Antibodies Phase 3,Phase 2,Phase 1
39 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
40 Antimitotic Agents Phase 3,Phase 2,Phase 1
41 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
42 Immunoglobulins Phase 3,Phase 2,Phase 1
43 Mitogens Phase 3,Phase 2,Phase 1
44 Anti-Infective Agents Phase 3,Phase 2,Phase 1
45 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
46 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
47 Antiviral Agents Phase 3,Phase 2,Phase 1
48 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
49 Vitamin B Complex Phase 3,Phase 2
50 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 323)

id Name Status NCT ID Phase Drugs
1 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
2 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
3 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
4 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
5 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
6 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
7 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
8 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
9 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
10 Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants Completed NCT00128661 Phase 3
11 Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis Completed NCT00052962 Phase 3
12 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
13 Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Completed NCT01640782 Phase 3 Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
14 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed NCT00917384 Phase 3 Placebo
15 Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer Completed NCT00140075 Phase 3 Epirubicin with Cyclophosphamide, followed by a Taxane;Epirubicin with a Taxane
16 Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. Completed NCT00056459 Phase 3 Vatalanib
17 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3 Cisplatin
18 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
19 Laparoscopic Approach to Cervical Cancer Recruiting NCT00614211 Phase 3
20 Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation Recruiting NCT02741856 Phase 2, Phase 3 Carboplatin;Paclitaxel;Cisplatin;Capecitabine
21 Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction Recruiting NCT01962246 Phase 2, Phase 3 Oxaliplatin; Capecitabine
22 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Recruiting NCT01523015 Phase 2, Phase 3
23 Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
24 Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma Recruiting NCT01404156 Phase 2, Phase 3 Epirubicin cisplatin 5-Fluorouracil
25 Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Recruiting NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
26 Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE- Recruiting NCT03019588 Phase 3 Paclitaxel
27 S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients Recruiting NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
28 Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer Recruiting NCT01786278 Phase 2, Phase 3
29 Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial Recruiting NCT02780921 Phase 3
30 NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) Recruiting NCT01726452 Phase 3 Epirubicin;Cisplatin;5 Flourouracil/ Capecitabine;Paclitaxel;Carboplatin
31 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Recruiting NCT02898077 Phase 3 Ramucirumab;Paclitaxel;Placebo
32 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Active, not recruiting NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
33 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3 cisplatin
34 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
35 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Active, not recruiting NCT01365156 Phase 3
36 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) Active, not recruiting NCT02370498 Phase 3 paclitaxel
37 Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Active, not recruiting NCT02545504 Phase 3 Andecaliximab;Placebo;Leucovorin;5-fluorouracil;Oxaliplatin
38 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Active, not recruiting NCT02314117 Phase 3 Ramucirumab;Capecitabine;Cisplatin;Placebo;Fluorouracil
39 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Active, not recruiting NCT02625623 Phase 3 Avelumab;Irinotecan;Paclitaxel
40 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3 cisplatin
41 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
42 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
43 Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer Terminated NCT01363466 Phase 3
44 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
45 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
46 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2 cisplatin
47 Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck Unknown status NCT00180921 Phase 2 Imatinib
48 Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT00763646 Phase 2 Taxotere, Cisplatin, and 5-FU
49 Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT01379807 Phase 2 panitumumab + docetaxel + cisplatino
50 Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma Unknown status NCT00964080 Phase 1, Phase 2 MBP-426/Leucovorin/5-FU

Search NIH Clinical Center for Cervical Adenocarcinoma

Genetic Tests for Cervical Adenocarcinoma

Anatomical Context for Cervical Adenocarcinoma

MalaCards organs/tissues related to Cervical Adenocarcinoma:

39
Cervix, Lung, Lymph Node, Salivary Gland, Thyroid, Breast, Prostate

Publications for Cervical Adenocarcinoma

Articles related to Cervical Adenocarcinoma:

(show top 50) (show all 324)
id Title Authors Year
1
Metastatic cervical adenocarcinoma to the orbital subperiosteal space. ( 28457305 )
2017
2
Cervical Adenocarcinoma Has a Poorer Prognosis and a Higher Propensity for Distant Recurrence Than Squamous Cell Carcinoma. ( 28604449 )
2017
3
Risk of persistent or recurrent neoplasia in conservatively treated women with cervical adenocarcinoma in situ with negative histological margins. ( 28181670 )
2017
4
Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: Example from Australia. ( 28720447 )
2017
5
Cervical Adenocarcinoma: Diagnosis of Human Papillomavirus-Positive and Human Papillomavirus-Negative Tumors. ( 28644686 )
2017
6
Isolated port site recurrence of node-negative clinical stage IB1 cervical adenocarcinoma. ( 28331901 )
2017
7
Assessment of anti-cancerous potential of 6-gingerol (Tongling White Ginger) and its synergy with drugs on human cervical adenocarcinoma cells. ( 28249781 )
2017
8
Role of positive peritoneal cytology in FIGO stage IB to IIB cervical adenocarcinoma. ( 28186628 )
2017
9
Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. ( 28102052 )
2017
10
Immunohistochemical Expression of the Tumor Suppressor Protein p16INK4a in Cervical Adenocarcinoma. ( 28245508 )
2017
11
Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. ( 28851799 )
2017
12
Should ovaries be removed or not in early-stage cervical adenocarcinoma: a multicenter retrospective study of 105 patients. ( 28631536 )
2017
13
Methods for Measuring and Staging a Uterine Cervical Adenocarcinoma Showing Intracystic Papillary Growth: A Case Report. ( 28700431 )
2017
14
Comparison of Cold-Knife Conization versus Loop Electrosurgical Excision for Cervical Adenocarcinoma In Situ (ACIS): A Systematic Review and Meta-Analysis. ( 28125627 )
2017
15
Case images: Cervical adenocarcinoma presenting with a terrible combination: a giant cardiac mass, cardiac tamponade and pulmonary embolism. ( 28045425 )
2016
16
Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study. ( 27227411 )
2016
17
Prevalence of HPV genotypes in cervical adenocarcinoma: a study in Greek women. ( 27569088 )
2016
18
Analysis of the expression and localization of tight junction transmembrane proteins, claudin-1, -4, -7, occludin and JAM-A, in human cervical adenocarcinoma. ( 26847087 )
2016
19
Cervical Adenocarcinoma: Are We Screening and Treating Patients Appropriately? ( 27529155 )
2016
20
Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis. ( 27977543 )
2016
21
The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation-wide multi-center retrospective study across China. ( 27554015 )
2016
22
Cervical adenocarcinoma with stromal micropapillary pattern. ( 26608235 )
2016
23
Comment on: Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. ( 27793441 )
2016
24
Human Leukocyte Antigen-DR Expression is Significantly Related to an Increased Disease-Free and Disease-Specific Survival in Patients With Cervical Adenocarcinoma. ( 27654088 )
2016
25
Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma. ( 27102248 )
2016
26
Incidence and survival trends of cervical adenocarcinoma in Italy: Cytology screening has become more effective in downstaging the disease but not in detecting its precursors. ( 27639249 )
2016
27
Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: a retrospective study and metaanalysis. ( 27133009 )
2016
28
Correlation between EGFR Expression and Radiosensitivity in Cervical Adenocarcinoma Cases. ( 27268625 )
2016
29
Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. ( 27566027 )
2016
30
Cytomorphology of Gastric-Type Cervical Adenocarcinoma on a ThinPrep Pap Test: Report of a p16-Positive Tumor Case. ( 27165398 )
2016
31
Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors. ( 27677664 )
2016
32
Uterine cervical adenocarcinoma metastasizing concurrently to eutopic and ectopic ovaries: A case report. ( 27005982 )
2016
33
Biology and treatment of cervical adenocarcinoma. ( 27198186 )
2016
34
Macrophage immigration inhibitory factor promotes cell proliferation and inhibits apoptosis of cervical adenocarcinoma. ( 25716200 )
2015
35
Prognostic factors affecting cervical adenocarcinoma: 10A years experience in a single institution. ( 25851496 )
2015
36
Laparoscopic hysterectomy with morcellation for a suspected uterine fibroid resulting in dissemination of cervical adenocarcinoma: A case report. ( 26076147 )
2015
37
Repeated episodes of spontaneous regression/progression of cervical adenocarcinoma after adjuvant chemoradiation therapy: a case report. ( 25985999 )
2015
38
Methanolic Extracts from Brown Seaweeds Dictyota cilliolata and Dictyota menstrualis Induce Apoptosis in Human Cervical Adenocarcinoma HeLa Cells. ( 25871374 )
2015
39
Prognostic evaluation of tumor-stroma ratio in patients with early stage cervical adenocarcinoma treated by surgery. ( 26028100 )
2015
40
CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway. ( 26404133 )
2015
41
Combination of external beam radiotherapy and Californium (Cf)-252 neutron intracavity brachytherapy is more effective in control of cervical squamous cell carcinoma than that of cervical adenocarcinoma. ( 26271794 )
2015
42
FoxP3(+) and IL-17(+) cells are correlated with improved prognosis in cervical adenocarcinoma. ( 25795131 )
2015
43
Clinicopathologic Factors of Cervical Adenocarcinoma Stages IB to IIB. ( 26495760 )
2015
44
The effect of coexisting squamous cell lesions on prognosis in patients with cervical adenocarcinoma in situ. ( 25956340 )
2015
45
Widespread recurrence 7 years after radical abdominal trachelectomy for early cervical adenocarcinoma. ( 25918655 )
2015
46
Patterns of Invasion of Cervical Adenocarcinoma as Predicators of Outcome. ( 26452210 )
2015
47
Robot-Assisted Laparoscopic Partial Colpectomy and Intracorporeal Ileal Conduit Urinary Diversion (Bricker) for Cervical Adenocarcinoma Recurrence. ( 26634161 )
2015
48
High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma. ( 25871737 )
2015
49
Comparison of cold knife cone biopsy and loop electrosurgical excision procedure in the management of cervical adenocarcinoma in situ: What is the gold standard? ( 25769659 )
2015
50
The complex relationship between human papillomavirus and cervical adenocarcinoma. ( 26334557 )
2015

Variations for Cervical Adenocarcinoma

Expression for Cervical Adenocarcinoma

Search GEO for disease gene expression data for Cervical Adenocarcinoma.

Pathways for Cervical Adenocarcinoma

Pathways related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 33)
id Super pathways Score Top Affiliating Genes
1 12.55 CDKN1A EGFR LAMC2 PTGS2 TP53
2
Show member pathways
12.47 CDKN1A EGFR ERBB2 TP53
3
Show member pathways
12.39 CDKN1A CDKN2A EGFR ERBB2 ESR1 RASSF1
4
Show member pathways
12.19 CDKN1A EGFR ERBB2 TP53
5
Show member pathways
12.19 EGFR ERBB2 ESR1 PTGS2
6 12.18 CDKN1A CDKN2A EGFR ERBB2 PTGS2 RASSF1
7 12.15 CDKN1A CDKN2A EGFR ERBB2 LAMC2 PTGS2
8
Show member pathways
12.11 CDKN1A EGFR ERBB2 TP53
9 12.07 CDKN1A EGFR PTGS2 TP53
10 12.07 CDKN1A EGFR ERBB2 ESR1 TP53
11 11.96 CDKN1A EGFR TP53
12 11.96 CDKN1A CDKN2A TP53
13 11.94 CDKN1A EGFR TP53
14
Show member pathways
11.92 EGFR ERBB2 TP53
15 11.9 EGFR PTGS2 TP53
16 11.89 CDKN1A CDKN2A ERBB2 TP53
17 11.87 CDKN1A PTGS2 TP53
18 11.86 CDKN1A CDKN2A EGFR TP53
19
Show member pathways
11.84 EGFR ERBB2 ESR1
20 11.82 CDKN1A CDKN2A TP53
21 11.78 CDKN1A EGFR ERBB2
22
Show member pathways
11.7 CDKN1A EGFR ERBB2 ESR1
23 11.68 CDKN1A LAMC2 PTGS2 TP53
24 11.6 CDKN1A EGFR ERBB2
25 11.57 EGFR ERBB2 TP53
26 11.57 CDKN1A CDKN2A ERBB2 TP53
27 11.44 CDKN1A PTGS2 TP53
28 11.33 CDKN1A CDKN2A EGFR TP53
29 11.26 ESR1 PTGS2 TP53
30 11.24 CDKN1A EGFR ESR1 PTGS2
31
Show member pathways
11 CDKN1A CDKN2A TP53
32 10.96 CDKN1A CDKN2A EGFR ERBB2 RASSF1 TP53
33 10.68 CDKN1A TP53

GO Terms for Cervical Adenocarcinoma

Cellular components related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.02 CDKN1A CDX2 ESR1 PTGS2 TP53

Biological processes related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.85 CDKN2A CDX2 EGFR ESR1 TP53
2 regulation of transcription from RNA polymerase II promoter GO:0006357 9.83 CDKN1A CDX2 EGFR ERBB2 ESR1
3 response to organic cyclic compound GO:0014070 9.72 CDKN1A EGFR PTGS2
4 negative regulation of cell growth GO:0030308 9.71 CDKN1A CDKN2A TP53
5 phosphatidylinositol-mediated signaling GO:0048015 9.69 EGFR ERBB2 TP53
6 response to estradiol GO:0032355 9.65 EGFR ESR1 PTGS2
7 positive regulation of fibroblast proliferation GO:0048146 9.58 CDKN1A EGFR ESR1
8 negative regulation of phosphorylation GO:0042326 9.57 CDKN1A CDKN2A
9 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.56 EGFR PTGS2
10 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.52 CDKN1A TP53
11 negative regulation of ERBB signaling pathway GO:1901185 9.49 EGFR ERBB2
12 cell cycle arrest GO:0007050 9.46 CDKN1A CDKN2A RASSF1 TP53
13 cellular response to epidermal growth factor stimulus GO:0071364 9.43 EGFR ERBB2 VIL1
14 negative regulation of immature T cell proliferation in thymus GO:0033088 9.37 CDKN2A ERBB2
15 signal transduction by p53 class mediator GO:0072331 9.32 CDKN1A TP53
16 Ras protein signal transduction GO:0007265 9.26 CDKN1A CDKN2A RASSF1 TP53
17 replicative senescence GO:0090399 8.8 CDKN1A CDKN2A TP53

Molecular functions related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.67 EGFR ESR1 PTGS2 TP53
2 protein phosphatase binding GO:0019903 9.33 EGFR ERBB2 TP53
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.32 CDKN1A CDKN2A
4 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.26 EGFR ERBB2
5 protein kinase binding GO:0019901 9.02 CDKN1A CDKN2A EGFR ESR1 TP53
6 nitric-oxide synthase regulator activity GO:0030235 8.96 EGFR ESR1

Sources for Cervical Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....